Pzena Investment Management LLC acquired a new position in USANA Health Sciences, Inc. (NYSE:USNA – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,205,587 shares of the company’s stock, valued at approximately $25,739,000. Pzena Investment Management LLC owned about 0.07% of USANA Health Sciences at the end of the most recent reporting period.
Several other large investors have also modified their holdings of the business. Versant Capital Management Inc grew its stake in shares of USANA Health Sciences by 1,472.3% during the second quarter. Versant Capital Management Inc now owns 1,588 shares of the company’s stock valued at $34,000 after buying an additional 1,487 shares during the last quarter. National Bank of Canada FI lifted its stake in shares of USANA Health Sciences by 166.6% during the 3rd quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock worth $53,000 after acquiring an additional 1,201 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of USANA Health Sciences by 382.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock worth $73,000 after acquiring an additional 1,901 shares during the last quarter. State of Wyoming purchased a new position in USANA Health Sciences during the 1st quarter valued at $57,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in USANA Health Sciences by 52.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock valued at $106,000 after acquiring an additional 1,327 shares during the period. Hedge funds and other institutional investors own 54.25% of the company’s stock.
Insider Buying and Selling at USANA Health Sciences
In other USANA Health Sciences news, Director John Turman Fleming sold 2,450 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $17.93, for a total value of $43,928.50. Following the completion of the sale, the director directly owned 4,230 shares in the company, valued at approximately $75,843.90. This represents a 36.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO G Doug Iiekking sold 5,360 shares of the company’s stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $18.75, for a total value of $100,500.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 13,869 shares of company stock valued at $261,441 in the last ninety days. Corporate insiders own 0.82% of the company’s stock.
Analysts Set New Price Targets
Check Out Our Latest Stock Report on USNA
USANA Health Sciences Stock Performance
Shares of NYSE:USNA opened at $12.79 on Tuesday. The firm’s 50 day simple moving average is $19.86 and its 200-day simple moving average is $19.28. USANA Health Sciences, Inc. has a one year low of $12.58 and a one year high of $32.32. The firm has a market cap of $236.14 million, a PE ratio of -10.57, a price-to-earnings-growth ratio of 1.47 and a beta of 0.73.
USANA Health Sciences (NYSE:USNA – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.50). USANA Health Sciences had a negative net margin of 2.43% and a positive return on equity of 3.41%. The firm had revenue of $223.27 million during the quarter, compared to analysts’ expectations of $235.00 million. USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS. Equities research analysts predict that USANA Health Sciences, Inc. will post 0.76 EPS for the current fiscal year.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.
Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.
Read More
- Five stocks we like better than USANA Health Sciences
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Want to see what other hedge funds are holding USNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for USANA Health Sciences, Inc. (NYSE:USNA – Free Report).
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
